


RORyt Inverse agonist 8

Cat. No.:	HY-122737
CAS No.:	2079892-79-6
Molecular Formula:	C ₂₆ H ₃₃ N ₇ O ₂
Molecular Weight:	475.59
Target:	ROR
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	RORyt Inverse agonist 8 is a potent, selective, orally bioavailable RORyt inverse agonist, with an IC ₅₀ of 19 nM for human RORyt-LBD ^[1] .								
IC₅₀ & Target	IC ₅₀ : 19 nM (RORyt) ^[1]								
In Vitro	<p>RORyt Inverse agonist 8 (Cpd 1) is a potent RORyt inhibitor and binds to the ligand binding domain (LBD) of RORyt^[1]. RORyt Inverse agonist 8 (0-10μM ;24 hours) results in complete attenuation of IL-17A secretion in a concentration-dependent manner with an IC₅₀ of 60 nM in HUT78 cells^[1].</p> <p>RORyt Inverse agonist 8 selectively suppresses human Th17 and Tc17 cell differentiation^[1].</p> <p>RORyt Inverse agonist 8 polarizes Th17 cells also blocks IL-17A production in a concentration-dependent manner with an IC₅₀ of 92 nM^[1].</p> <p>RORyt Inverse agonist 8 reduces Th17 cell-associated mRNA expression including IL17A, IL17F, IL26, IL23R and CCR6 in a concentration-dependent fashion^[1].</p> <p>RORyt Inverse agonist 8 alters epigenetic regulation at the IL17A and IL23R gene promoters without impairing the DNA binding activity of RORyt^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>								
In Vivo	<p>RORyt Inverse agonist 8 (15 mg/kg, 45 mg/kg ; i.g.; twice daily; for 7 days) ameliorates antigen-induced arthritis (AiA) responses in Lewis rats^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Female Lewis rats (190–220 g)^[1]</td> </tr> <tr> <td>Dosage:</td> <td>15 mg/kg, 45 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; twice daily; for 7 days</td> </tr> <tr> <td>Result:</td> <td>Ameliorates antigen-induced arthritis (AiA) responses in Lewis rats.</td> </tr> </table>	Animal Model:	Female Lewis rats (190–220 g) ^[1]	Dosage:	15 mg/kg, 45 mg/kg	Administration:	Oral gavage; twice daily; for 7 days	Result:	Ameliorates antigen-induced arthritis (AiA) responses in Lewis rats.
Animal Model:	Female Lewis rats (190–220 g) ^[1]								
Dosage:	15 mg/kg, 45 mg/kg								
Administration:	Oral gavage; twice daily; for 7 days								
Result:	Ameliorates antigen-induced arthritis (AiA) responses in Lewis rats.								

REFERENCES

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA